Human BNP
Phase 1Small molecule
Human BNP is one of 102 small molecule programs targeting Dyspepsia. It is currently in Phase 1.
3
Indications
4
Total Trials
0
Active Trials
101
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
232 competitors in Myocardial Infarction
#DrugCompanyPhaseTrials
1Lovenox
SanofiPhase 3
Eliquis
Bristol-Myers SquibbPhase 3
Zetia
OOrganon and Co
Phase 3
Ticlid
RochePhase 3
Darapladib
GSKPhase 3
N-Acetylcystein
SSeoul National University Hospital
Phase 3
Dutogliptin Tartrate
RRecardio, Inc.
Phase 3
Repatha
AmgenPreclinical
Tnkase
RochePreclinical
Activase
RochePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Myocardial Infarction1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Human BNP. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- MMayo Clinic